Prof. Dr. med. Damian Wild

Beck, Julia, Siebenhüner, Alexander, Wild, Damian, Christ, Emanuel, & Refardt, Julie. (2024). Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms. Endocrine-Related Cancer, 31. https://doi.org/10.1530/erc-23-0235

Doncic, Nikola, Zech, Christoph J., Wild, Damian, Bachmann, Helga, Mallaev, Makhmudbek, Tsvetkov, Nikolay, Hojski, Aljaz, Takes, Martin T. L., & Lardinois, Didier. (2024). CT-guided percutaneous marking of small pulmonary nodules with [ 99m Tc]Tc-Macrosalb is very accurate and allows minimally invasive lung-sparing resection: a single-centre quality control. European Journal of Nuclear Medicine and Molecular Imaging, 51, 2980–2987. https://doi.org/10.1007/s00259-023-06410-1

Eigler, Christopher, McDougall, Lisa, Bauman, Andreas, Bernhardt, Peter, Hentschel, Michael, Blackham, Kristine A., Nicolas, Guillaume, Fani, Melpomeni, Wild, Damian, & Cordier, Dominik. (2024). Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study. Journal of Nuclear Medicine, 65, 573–579. https://doi.org/10.2967/jnumed.123.266817

Fricke, Julia, Westerbergh, Frida, McDougall, Lisa, Favaretto, Chiara, Christ, Emanuel, Nicolas, Guillaume P., Geistlich, Susanne, Borgna, Francesca, Fani, Melpomeni, Bernhardt, Peter, van der Meulen, Nicholas P., Müller, Cristina, Schibli, Roger, & Wild, Damian. (2024). First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([ 161 Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06641-w

Friebe, Liene, Freitag, Martin T., Braun, Martin, Nicolas, Guillaume, Bauman, Andreas, Bushnell, David, Christ, Emanuel, & Wild, Damian. (2024). Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis. Journal of Nuclear Medicine, 65, 228–235. https://doi.org/10.2967/jnumed.123.265894

Ivanova, Vanesa-Sindi, Davies, John, Menter, Thomas, Wild, Damian, Müller, Anne, Krasniqi, Fatime, Stenner, Frank, Papachristofilou, Alexandros, Dirnhofer, Stefan, & Tzankov, Alexandar. (2024). Primary bone diffuse large B-cell lymphoma (PB-DLBCL): a distinct extranodal lymphoma of germinal centre origin, with a common EZB-like mutational profile and good prognosis. Histopathology, 84, 525–538. https://doi.org/10.1111/his.15096

Neubauer, Moritz C., Nicolas, Guillaume P., Bauman, Andreas, Fani, Melpomeni, Nitzsche, Egbert, Afshar-Oromieh, Ali, Forrer, Flavio, Rentsch, Cyril, Stenner, Frank, Templeton, Arnoud, Schäfer, Niklaus, Wild, Damian, & Chirindel, Alin. (2024). Early response monitoring during [ 177 Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. European Journal of Nuclear Medicine and Molecular Imaging, 51, 1185–1193. https://doi.org/10.1007/s00259-023-06536-2

Rottenburger, Christof, Hentschel, Michael, Fürstner, Markus, McDougall, Lisa, Kottoros, Danijela, Kaul, Felix, Mansi, Rosalba, Fani, Melpomeni, Vija, A. Hans, Schibli, Roger, Geistlich, Susanne, Behe, Martin, Christ, Emanuel R., & Wild, Damian. (2024). In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [ 177 Lu]Lu-PP-F11N in humans: the lumed phase 0b study. EJNMMI Research, 14. https://doi.org/10.1186/s13550-024-01101-w

Schürrle, Seval Beykan, Eberlein, Uta, Ansquer, Catherine, Beauregard, Jean-Mathieu, Durand-Gasselin, Lucie, Grønbæk, Henning, Haug, Alexander, Hicks, Rodney J., Lenzo, Nat P., Navalkissoor, Shaunak, Nicolas, Guillaume P., Pais, Ben, Volteau, Magali, Wild, Damian, McEwan, Alexander, & Lassmann, Michael. (2024). Dosimetry and pharmacokinetics of [ 177 Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06682-1

Askari E, Moghadam SZ, Wild D, Delpassand E, Baldari S, Nilica B, Hartrampf PE, Kong G, Grana CM, Alexander Walter M, Capoccetti F, Kasi PM, & Strosberg J. (2023). Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review. Journal of Nuclear Medicine Technology, 51(1), 22–25. https://doi.org/10.2967/jnmt.122.264904

Mallaev, Makhmudbek, Chirindel, Alin-Florin, Lardinois, Didier, Tamm, Michael, Vija, Alexander Hans, Cachovan, Michal, Wild, Damian, Stolz, Daiana, & Nicolas, Guillaume P. (2023). 3D-Quantitated Single Photon Emission Computed Tomography/Computed Tomography: Impact on intended Management Compared to Lung Perfusion Scan in Marginal Candidates for Pulmonary Resection [Journal-article]. Clinical Lung Cancer, 24(7), 621–630. https://doi.org/10.1016/j.cllc.2023.07.006

Maushart, Claudia Irene, Sun, Wenfei, Othman, Alaa, Ghosh, Adhideb, Senn, Jaël Rut, Fischer, Jonas Gabriel William, Madoerin, Philipp, Loeliger, Rahel Catherina, Benz, Robyn Melanie, Takes, Martin, Zech, Christoph Johannes, Chirindel, Alin, Beuschlein, Felix, Reincke, Martin, Wild, Damian, Bieri, Oliver, Zamboni, Nicola, Wolfrum, Christian, & Betz, Matthias Johannes. (2023). Effect of high-dose glucocorticoid treatment on human brown adipose tissue activity: a randomised, double-blinded, placebo-controlled cross-over trial in healthy men. eBioMedicine, 96. https://doi.org/10.1016/j.ebiom.2023.104771

Schmidlin, Moira, Sadowski, Samira M., Siebenhüner, Alexander, Wild, Damian, Christ, Emanuel, & Refardt, Julie. (2023). Improvement of Lung NET Management through Standardized Care—A Swiss Nationwide Observational Study. Cancers, 15. https://doi.org/10.3390/cancers15082270

Sira, Lívia, Zsíros, Noémi, Bidiga, László, Barna, Sándor, Kanyári, Zsolt, Nagy, Edit B., Guillaume, Nicolas, Wild, Damian, Rázsó, Katalin, Andó, Szilvia, Balogh, István, Nagy, Endre V., & Balogh, Zoltán. (2023). Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1095815

Wild, Damian, Grønbæk, Henning, Navalkissoor, Shaunak, Haug, Alexander, Nicolas, Guillaume P., Pais, Ben, Ansquer, Catherine, Beauregard, Jean-Mathieu, McEwan, Alexander, Lassmann, Michael, Pennestri, Daniele, Volteau, Magali, Lenzo, Nat P., & Hicks, Rodney J. (2023). A phase I/II study of the safety and efficacy of [ 177 Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 51, 183–195. https://doi.org/10.1007/s00259-023-06383-1

Varum F, Thorne H, Bravo R, Gilgen D, Hartig C, Nicolas GP, Wild D, Liakoni E, & Haschke M. (2022). Targeted colonic release formulations of mesalazine – A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis. International Journal of Pharmaceutics, 625, 122055. https://doi.org/10.1016/j.ijpharm.2022.122055

Hasegawa S., Kobayashi N., Wild D., Kaul F., Okubo N., Suzuki A., Kurita Y., Takano S., Nakajima A., & Ichikawa Y. (2022). Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. Cancers, 14(14). https://doi.org/10.3390/cancers14143317

Refardt J, Hofland J, Wild D., & Christ E. (2022). Molecular Imaging of Neuroendocrine Neoplasms. Journal of Clinical Endocrinology and Metabolism, 107(7), E2662–E2670. https://doi.org/10.1210/clinem/dgac207

Christ E, Wild D, & Refardt J. (2022). Molecular Imaging in neuroendocrine neoplasias. Presse Medicale, 51(2), 104115. https://doi.org/10.1016/j.lpm.2022.104115

Freitag MT, Bremerich J, Wild D, Haaf P, Zellweger MJ, & Caobelli F. (2022). Quantitative myocardial perfusion 82Rb-PET assessed by hybrid PET/coronary-CT: Normal values and diagnostic performance. Journal of Nuclear Cardiology, 29(2), 464–473. https://doi.org/10.1007/s12350-020-02264-4

Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O’Toole D, Sundin A, & Prasad V. (2022). ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of Neuroendocrinology, 34(3), e13040. https://doi.org/10.1111/jne.13040

Fani, Melpomeni, Mansi, Rosalba, Nicolas, Guillaume P., & Wild, Damian. (2022). Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals. Cancers, 14(5). https://doi.org/10.3390/cancers14051172

Hayes AR, Crawford A, Al Riyami K, Tang C, Bomanji J, Baldeweg SE, Wild D, Morganstein D, Harry A, Grozinsky-Glasberg S, Oleinikov K, Khoo B, Caplin ME, Nicolas GP, & Grossman AB. (2021). Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. Journal of Clinical Endocrinology and Metabolism, 106(12), E4903–E4916. https://doi.org/10.1210/clinem/dgab588

Refardt J, Hofland J, Wild D, & Christ E. (2021). New Directions in Imaging Neuroendocrine Neoplasms. Current Oncology Reports, 23(12), 143. https://doi.org/10.1007/s11912-021-01139-2

Theiler D., Cattaneo M, Dierickx L.O., Igaz P., Grozinsky-Glasberg S, Bournaud C., O’dorisio T., Sue O’Dorisio M., Wild D., Christ E., & Nicolas GP. (2021). Safety and efficacy of peptide-receptor radionuclide therapy in elderly neuroendocrine tumor patients. Cancers, 13(24). https://doi.org/10.3390/cancers13246290

Kobayashi N, Wild D, Kaul F, Shimamura T, Takano S, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, & Ichikawa Y. (2021). Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 28(9), 727–739. https://doi.org/10.1002/jhbp.1014

Refardt J, Hofland J, Kwadwo A, Nicolas GP, Rottenburger C, Fani M, Wild D, & Christ E. (2021). Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. Reviews in Endocrine and Metabolic Disorders, 22(3), 581–594. https://doi.org/10.1007/s11154-020-09552-x

Wild D, Antwi K, Fani M, & Christ ER. (2021). Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic? Journal of Nuclear Medicine, 62(Suppl 2), 44S–50S. https://doi.org/10.2967/jnumed.120.246009

Antwi K, Wiesner P., Merkle E.M., Zech CJ, Boll DT, Wild D, Christ E, & Heye T. (2021). Research article investigating difficult to detect pancreatic lesions: Characterization of benign pancreatic islet cell tumors using multiparametric pancreatic 3-T MRI. PLoS ONE, 16(6 June 2021), e0253078. https://doi.org/10.1371/journal.pone.0253078

Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, et al. (2021). Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 146, 56–73. https://doi.org/10.1016/j.ejca.2021.01.008

Braun M, Cachovan M, Kaul F, Caobelli F, Bäumer M, Hans Vija A, Pagenstert G, Wild D, & Kretzschmar M. (2021). Accuracy comparison of various quantitative [99mTc]Tc-DPD SPECT/CT reconstruction techniques in patients with symptomatic hip and knee joint prostheses. EJNMMI Research, 11(1), 60. https://doi.org/10.1186/s13550-021-00794-7

Preisig, Daniel, Varum, Felipe, Bravo, Roberto, Hartig, Claudia, Spleiss, Johannes, Abbes, Sonia, Caobelli, Federico, Wild, Damian, Puchkov, Maxim, Huwyler, Jörg, & Haschke, Manuel. (2021). Colonic delivery of metronidazole-loaded capsules for local treatment of bacterial infections: a clinical pharmacoscintigraphy study. European Journal of Pharmaceutics and Biopharmaceutics, 165, 22–30. https://doi.org/10.1016/j.ejpb.2021.05.002

Schaerli N, Abächerli R, Walter J, Honegger U, Puelacher C, Rinderknecht T, Müller D, Boeddinghaus J, Nestelberger T, Strebel I, Badertscher P, Badertscher P, du Fay de Lavallaz J, Twerenbold R, Wussler D, Hofer J, Leber R, Kaiser C, Osswald S, et al. (2020). Incremental value of high-frequency QRS analysis for diagnosis and prognosis in suspected exercise-induced myocardial ischaemia. European Heart Journal: Acute Cardiovascular Care, 9(8), 836–847. https://doi.org/10.1177/2048872619842988

Häfliger S, Seidel AK, Schoch E, Reichmann J, Wild D, Steinmann-Schwager S, & Pless M. (2020). Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor (Patent No. 3). 13(3), Article 3. https://doi.org/10.1159/000510334

Caobelli F, Braun M, Haaf P, Wild D, & Zellweger MJ. (2020). Quantitative 99mTc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores. Journal of Nuclear Cardiology, 27(5), 1456–1463. https://doi.org/10.1007/s12350-019-01893-8

Antwi K, Hepprich M, Müller NA, Reubi JC, Fani M, Rottenburger C, Nicolas G, Kaul F, Christ ER, & Wild D. (2020). Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging. Clinical Nuclear Medicine, 45(9), E386–E392. https://doi.org/10.1097/RLU.0000000000003124

Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, & Wild D. (2020). Cholecystokinin 2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma: Results of the lumed phase 0a study. Journal of Nuclear Medicine, 61(4), 520–523. https://doi.org/10.2967/jnumed.119.233031

Christ E, Antwi K, Fani M, & Wild D. (2020). Innovative imaging of insulinoma: The end of sampling? a review. Endocrine-Related Cancer, 27(4), R79–R92. https://doi.org/10.1530/ERC-19-0476

Fischer JGW, Maushart CI, Becker AS, Müller J, Madoerin P, Chirindel A, Wild D, Ter Voert EEGW, Bieri O, Burger I, & Betz MJ. (2020). Comparison of [18F]FDG PET/CT with magnetic resonance imaging for the assessment of human brown adipose tissue activity. EJNMMI Research, 10(1), 85. https://doi.org/10.1186/s13550-020-00665-7

Hepprich M, Antwi K, Waser B, Reubi JC, Wild D, Christ ER, & Christ ER. (2020). Brunner’s Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging [Hindawi Limited410 Park Avenue, 15th Floor, 287 pmbNew YorkNY 10022]. 2020, 4510910. https://doi.org/10.1155/2020/4510910

Antwi K, Nicolas G, Fani M, Heye T, Pattou F, Grossman A, Chanson P, Reubi JC, Perren A, Gloor B, Vogt DR, Wild D, & Christ E. (2019). Ga-Exendin-4 PET/CT Detects Insulinomas in Patients with Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. Journal of Clinical Endocrinology and Metabolism, 104(12), 5843–5852. https://doi.org/10.1210/jc.2018-02754

Buitinga M, Jansen T, van der Kroon I, Woliner-van der Weg W, Boss M, Janssen M, Aarntzen E, Béhé M, Wild D, Visser E, Brom M, & Gotthardt M. (2019). Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients. Journal of Nuclear Medicine, 60(6), 812–816. https://doi.org/10.2967/jnumed.118.219980

Wolf KI, Jha A, van Berkel A, Wild D, Janssen I, Millo CM, Janssen MJR, Gonzales MK, Timmers HJKM, & Pacak K. (2019). Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE (Patent No. 3). 53(3), Article 3. https://doi.org/10.1007/s13139-019-00579-w

Antwi K, Nicolas G, Fani M, Christ E, & Wild D. (2019). Volume Replacement Fluid Demarks Benign Insulinoma with 68Ga-DOTA-Exendin-4 PET/CT. Clinical Nuclear Medicine, 44(5), E347–E348. https://doi.org/10.1097/RLU.0000000000002522

Antwi K, Nicolas G, Wild D, & Christ E. (2019). Molecular imaging for neuroendocrine tumours. Swiss Medical Weekly, 149(9-10), w20017. https://doi.org/10.4414/smw.2019.20017

Beykan S, Fani M, Jensen SB, Nicolas G, Wild D, Kaufmann J, & Lassmann M. (2019). In vivo biokinetics of 177Lu-OPS201 in mice and pigs as a model for predicting human dosimetry. Contrast Media and Molecular Imaging, 2019, 6438196. https://doi.org/10.1155/2019/6438196

Honegger, Ursina, Walter, Joan E., Müller, Deborah, Puelacher, Christian, Schaerli, Nicolas, Twerenbold, Raphael, Badertscher, Patrick, Boeddinghaus, Jasper, Nestelberger, Thomas, du Fay de Lavallaz, Jeanne, Wussler, Desiree, Pfister, Otmar, Jeger, Raban, Kaiser, Christoph, Wild, Damian, Schmidt-Trucksäss, Arno, Reichlin, Tobias, & Müller, Christian. (2019). Prevalence and determinants of exercise-induced left ventricular dysfunction in patients with coronary artery disease. European Journal of Clinical Investigation, 49(6), e13112. https://doi.org/10.1111/eci.13112

Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, & Fani M. (2019). Targeting of the cholecystokinin-2 receptor with the minigastrin analog 177 Lu-DOTA-PP-F11N: Does the use of protease inhibitors further improve in vivo distribution? Journal of Nuclear Medicine, 60(3), 393–399. https://doi.org/10.2967/jnumed.118.207845

Antwi K, Fani M, Heye T, Nicolas G, Rottenburger C, Kaul F, Merkle E, Zech CJ, Boll D, Vogt DR, Gloor B, Christ E, & Wild D. (2018). Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. European Journal of Nuclear Medicine and Molecular Imaging, 45(13), 2318–2327. https://doi.org/10.1007/s00259-018-4101-5

Valente LG, Antwi K, Nicolas GP, Wild D, & Christ E. (2018). Clinical presentation of 54 patients with endogenous hyperinsulinaemic hypoglycaemia: a neurological chameleon (observational study). Swiss Medical Weekly, 148, w14682. https://doi.org/10.4414/smw.2018.14682

Omlin, Aurelius, Spahn, Martin, Beyer, Jörg, Eberli, Daniel, Gillessen, Silke, Jochum, Wolfram, Kueng, Marc, Nitzsche, Egbert, Rentsch, Cyrill A, Roggero, Enrico, Schmid, Hans-Peter, Stenner, Frank, Templeton, Arnoud J, Templeton, Arnoud J, Wild, Damian, Wyler, Stephen, Zwahlen, Daniel, & Cathomas, Richard. (2018). [Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]. Praxis, 107(19), 1043–1051. https://doi.org/10.1024/1661-8157/a003054

Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, Reubi JC, Rivier JEF, Maecke HR, Fani M, & Wild D. (2018). Safety, Biodistribution, and Radiation Dosimetry of (68)Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 59(6), 909–914. https://doi.org/10.2967/jnumed.117.199737

Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, & Wild D. (2018). Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 59(6), 915–921. https://doi.org/10.2967/jnumed.117.199760

Nicolas GP, Wild D, & Fani M. (2018). Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists. (Patent No. 3). 59(3), Article 3. https://doi.org/10.2967/jnumed.117.203703

Badertscher, Patrick, Strebel, Ivo, Honegger, Ursina, Schaerli, Nicolas, Müller, Deborah, Puelacher, Christian, Wagener, Max, Abächerli, Roger, Walter, Joan, Sabti, Zaid, Sazgary, Lorraine, Marbot, Stella, du Fay de Lavallaz, Jeanne, Twerenbold, Raphael, Boeddinghaus, Jasper, Nestelberger, Thomas, Kozhuharov, Nikola, Breidthardt, Tobias, Shrestha, Samyut, et al. (2018). Automatically computed ECG algorithm for the quantification of myocardial scar and the prediction of mortality. Clinical research in cardiology, 107(9), 824–835. https://doi.org/10.1007/s00392-018-1253-z

Müller, Deborah, Puelacher, Christian, Honegger, Ursina, Walter, Joan E., Badertscher, Patrick, Schaerli, Nicolas, Strebel, Ivo, Twerenbold, Raphael, Boeddinghaus, Jasper, Nestelberger, Thomas, Hollenstein, Christina, du Fay de Lavallaz, Jeanne, Jeger, Raban, Kaiser, Christoph, Wild, Damian, Rentsch, Katharina, Buser, Andreas, Zellweger, Michael, Reichlin, Tobias, & Müller, Christian. (2018). Direct Comparison of Cardiac Troponin T and I Using a Uniform and a Sex-Specific Approach in the Detection of Functionally Relevant Coronary Artery Disease. Clinical Chemistry, 64(11), 1596–1606. https://doi.org/10.1373/clinchem.2018.286971

Puelacher, Christian, Wagener, Max, Honegger, Ursina, Assadian, Mustafa, Schaerli, Nicolas, Müller, Deborah, Strebel, Ivo, Twerenbold, Raphael, Boeddinghaus, Jasper, Nestelberger, Thomas, Wildi, Karin, Sabti, Zaid, Sazgary, Lorraine, Badertscher, Patrick, du Fay de Lavallaz, Jeanne, Marbot, Stella, Kaiser, Christoph, Wild, Damian, Zellweger, Michael J., et al. (2018). Combining high-sensitivity cardiac troponin and B-type natriuretic peptide in the detection of inducible myocardial ischemia. Clinical Biochemistry, 52, 33–40. https://doi.org/10.1016/j.clinbiochem.2017.10.014

Walter, Joan E., Honegger, Ursina, Puelacher, Christian, Müller, Deborah, Wagener, Max, Schaerli, Nicolas, Strebel, Ivo, Twerenbold, Raphael, Boeddinghaus, Jasper, Nestelberger, Thomas, Sazgary, Lorraine, Marbot, Stella, du Fay de Lavallaz, Jeanne, Kaiser, Christoph, Osswald, Stefan, Wild, Damian, Rentsch, Katharina, Zellweger, Michael, Reichlin, Tobias, & Müller, Christian. (2018). Prospective Validation of a Biomarker-Based Rule Out Strategy for Functionally Relevant Coronary Artery Disease. Clinical Chemistry, 64(2), 386–395. https://doi.org/10.1373/clinchem.2017.277210

Katona B.W., Roccaro GA, Soulen MC, Yang YX, Bennett B.J., Riff BP, Glynn RA, Wild D, Nicolas G.P., Pryma DA, Teitelbaum U.R., & Metz DC. (2017). Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis. Pancreas, 46(9), 1121–1126. https://doi.org/10.1097/mpa.0000000000000919

Fani M, Nicolas GP, & Wild D. (2017). Somatostatin Receptor Antagonists for Imaging and Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 58(Suppl 2), 61S–66S. https://doi.org/10.2967/jnumed.116.186783

Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, & Fani M. (2017). Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 58(9), 1435–1441. https://doi.org/10.2967/jnumed.117.191684

Puelacher C, Wagener M, Abächerli R, Honegger U, Lhasam N, Schaerli N, Prêtre G, Strebel I, Twerenbold R, Boeddinghaus J, Nestelberger T, Rubini Giménez M, Hillinger P, Wildi K, Sabti Z, Badertscher P, Cupa J, Kozhuharov N, du Fay de Lavallaz J, et al. (2017). Diagnostic value of ST-segment deviations during cardiac exercise stress testing: Systematic comparison of different ECG leads and time-points. International Journal of Cardiology, 238, 166–172. https://doi.org/10.1016/j.ijcard.2017.02.079

Wan MYS, Endozo R, Michopoulou S, Shortman R, Rodriguez-Justo M, Menezes L, Yusuf S, Richards T, Wild D, Waser B, Reubi JC, & Groves A. (2017). PET/CT Imaging of Unstable Carotid Plaque with (68)Ga-Labeled Somatostatin Receptor Ligand. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 58(5), 774–780. https://doi.org/10.2967/jnumed.116.181438

Wagener M, Abächerli R, Honegger U, Schaerli N, Prêtre G, Twerenbold R, Puelacher C, Sunier G, Reddiess P, Rubini Gimenez M, Wildi K, Boeddinghaus J, Nestelberger T, Badertscher P, Sabti Z, Schmid R, Leber R, Widmer DF, Shrestha S, et al. (2017). Diagnostic and Prognostic Value of Lead aVR During Exercise Testing in Patients Suspected of Having Myocardial Ischemia. The American Journal of Cardiology, 119(7), 959–966. https://doi.org/10.1016/j.amjcard.2016.11.056

Sauter AW, Stieltjes B, Weikert T, Gatidis S, Wiese M, Klarhöfer M, Wild D, Lardinois D, Bremerich J, & Sommer G. (2017). The Spatial Relationship between Apparent Diffusion Coefficient and Standardized Uptake Value of (18)F-Fluorodeoxyglucose Has a Crucial Influence on the Numeric Correlation of Both Parameters in PET/MRI of Lung Tumors. Contrast media & molecular imaging, 2017, 8650853. https://doi.org/10.1155/2017/8650853

Cuthbertson DJ, Banks M, Khoo B, Antwi K, Christ E, Campbell F, Raraty M, & Wild D. (2016). Application of Ga(68) -DOTA-exendin-4 PET/CT to localize an occult insulinoma. (Patent No. 5). 84(5), Article 5. https://doi.org/10.1111/cen.12973

Breuer TG, Breuer HL, Menge BA, Giese A, Uhl W, Schmidt WE, Tannapfel A, Wild D, Nauck MA, & Meier JJ. (2016). [Recurrent hypoglycemia due to an occult insulinoma]. Der Internist, 57(4), 385–389. https://doi.org/10.1007/s00108-016-0020-3

Sou SM, Puelacher C, Twerenbold R, Wagener M, Honegger U, Reichlin T, Schaerli N, Pretre G, Abächerli R, Jaeger C, Rubini Gimenez M, Wild D, Rentsch KM, Zellweger MJ, & Mueller C. (2016). Direct comparison of cardiac troponin I and cardiac troponin T in the detection of exercise-induced myocardial ischemia. Clinical Biochemistry, 49(6), 421–432. https://doi.org/10.1016/j.clinbiochem.2015.12.005

Lee G, Twerenbold R, Tanglay Y, Reichlin T, Honegger U, Wagener M, Jaeger C, Rubini Gimenez M, Hochgruber T, Puelacher C, Radosavac M, Kreutzinger P, Stallone F, Hillinger P, Krivoshei L, Herrmann T, Mayr R, Freese M, Wild D, et al. (2016). Clinical benefit of high-sensitivity cardiac troponin i in the detection of exercise-induced myocardial ischemia. American Heart Journal, 173, 8–17. https://doi.org/10.1016/j.ahj.2015.11.010

Baumann T, Rottenburger C, Nicolas G, & Wild D. (2016). Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging. Best Practice & Research. Clinical Endocrinology & Metabolism, 30(1), 45–57. https://doi.org/10.1016/j.beem.2016.01.003

Christ E, Wild D, Antwi K, Waser B, Fani M, Schwanda S, Heye T, Schmid C, Baer HU, Perren A, & Reubi JC. (2015). Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT. Endocrine, 50(3), 821–823. https://doi.org/10.1007/s12020-015-0633-7

Riff BP, Yang YX, Soulen MC, Pryma DA, Bennett B, Wild D, Nicolas G, Teitelbaum UR, & Metz DC. (2015). Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors. Clinical nuclear medicine, 40(11), 845–850. https://doi.org/10.1097/rlu.0000000000000935

Zürcher S, Honegger U, Wagener M, Lee G, Stallone F, Marxer T, Puelacher C, Schumacher C, Sou SM, Twerenbold R, Reichlin T, Hochgruber T, Tanglay Y, Freese M, Wild D, Rentsch K, Osswald S, Zellweger M, & Mueller C. (2015). Delayed release of brain natriuretic peptide to identify myocardial ischaemia. European Journal of Clinical Investigation, 45(11), 1175–1183. https://doi.org/10.1111/eci.12535

Maas O, Joseph GB, Sommer G, Wild D, & Kretzschmar M. (2015). Association between cartilage degeneration and subchondral bone remodeling in patients with knee osteoarthritis comparing MRI and (99m)Tc-DPD-SPECT/CT. Osteoarthritis and Cartilage, 23(10), 1713–1720. https://doi.org/10.1016/j.joca.2015.05.014

Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, Gloor B, Christ E, & Wild D. (2015). Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 56(7), 1075–1078. https://doi.org/10.2967/jnumed.115.157768

Tanglay Y, Twerenbold R, Lee G, Wagener M, Honegger U, Puelacher C, Reichlin T, Mann S, Druey S, Hochgruber T, Zürcher S, Radosavac M, Kreutzinger P, Pretre G, Stallone F, Hillinger P, Jaeger C, Rubini Gimenez M, Freese M, et al. (2015). Incremental value of a single high-sensitivity cardiac troponin i Measurement to rule out myocardial ischemia. American Journal of Medicine, 128(6), 638–646. https://doi.org/10.1016/j.amjmed.2015.01.009

Buechel, Ronny R., Kaufmann, Beat A., Tobler, Daniel, Wild, Damian, & Zellweger, Michael J. (2015). Non-invasive nuclear myocardial perfusion imaging improves the diagnostic yield of invasive coronary angiography. European Heart Journal - Cardiovascular Imaging, 16(8), 842–847. https://doi.org/10.1093/ehjci/jev095

Wenning AS, Kirchner P, Antwi K, Fani M, Wild D, Christ E, & Gloor B. (2015). Preoperative Glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases. Patient Safety in Surgery, 9, 23. https://doi.org/10.1186/s13037-015-0064-7

Christ,Emanuel, Wild,Damian, Antwi,Kwadwo, Waser,Beatrice, Fani,Melpomeni, Schwanda,Stefanie, Heye,Tobias, Schmid,Christoph, Baer,Hans Ulrich, Perren,Aurel, & Reubi,Jean Claude. (2015). Preoperative localization of adult nesidioblastosis using (68)Ga-DOTA-exendin-4-PET/CT. Endocrine, 50(3), 821–823.

Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JE, Reubi JC, Maecke HR, & Weber WA. (2014). Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 55(8), 1248–1252. https://doi.org/10.2967/jnumed.114.138834

Zellweger MJ, Zellweger MJ, Fahrni G, Ritter M, Jeger RV, Wild D, Buser P, Kaiser C, Osswald S, Pfisterer ME, & BASKET Investigators. (2014). Prognostic value of “routine” cardiac stress imaging 5 years after percutaneous coronary intervention: the prospective long-term observational BASKET (Basel Stent Kosteneffektivitäts Trial) LATE IMAGING study. JACC. Cardiovascular Interventions, 7(6), 615–621. https://doi.org/10.1016/j.jcin.2014.01.161

Lee G, Sou SM, Twerenbold R, Reichlin T, Oshima S, Hochgruber T, Zürcher S, Matter D, Tanglay Y, Freese M, Honegger U, Wild D, Rentsch K, Osswald S, Zellweger MJ, & Mueller C. (2014). B-type natriuretic peptide and clinical judgment in the detection of exercise-induced myocardial ischemia. American Journal of Medicine, 127(5), 427–435. https://doi.org/10.1016/j.amjmed.2014.01.009

Wicki, Andreas, Wild, Damian, Prêtre, Vincent, Mansi, Rosalba, Orleth, Annette, Reubi, Jean-Claude, Rochlitz, Christoph, Mamot, Christoph, Mäcke, Helmut R, & Christofori, Gerhard. (2014). Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors. EJNMMI Research, 4(1), 9. https://doi.org/10.1186/2191-219x-4-9

Christ E, Wild,Damian, Ederer,Susanne, Béhé,Martin, Nicolas,Guillaume, Caplin,Martyn E, Brändle,Michael, Clerici,Thomas, Fischli S, Stettler,Christoph, Ell,Peter J, Seufert,Jochen, Gloor,Beat, Perren,Aurel, Reubi,Jean Claude, & Forrer F. (2013). Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. The Lancet. Diabetes & Endocrinology, 1(2), 115–122. https://doi.org/10.1016/s2213-8587(13)70049-4

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, & Caplin ME. (2013). Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(3), 364–372. https://doi.org/10.2967/jnumed.112.111724

Körner M, Christ E., Wild D, & Reubi JC. (2012). Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Frontiers in Endocrinology, 3(DEC). https://doi.org/10.3389/fendo.2012.00158

Win T, Screaton NJ, Porter J, Endozo R, Wild D, Kayani I, Dickson J, Shortman RI, Reubi JC, Ell PJ, & Groves AM. (2012). Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[18F]fluoro-D-glucose. Molecular imaging, 11(2), 91–98.

Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC, Maecke HR, & Weber WA. (2011). First clinical evidence that imaging with somatostatin receptor antagonists is feasible. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 52(9), 1412–1417. https://doi.org/10.2967/jnumed.111.088922

Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, Provencher-Bolliger A, Reubi JC, & Maecke HR. (2011). Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Research, 71(3), 1009–1018. https://doi.org/10.1158/0008-5472.CAN-10-1186

Wild, Damian, Christ, Emanuel, Caplin, Martyn E, Kurzawinski, Tom R, Forrer, Flavio, Brändle, Michael, Seufert, Jochen, Weber, Wolfgang A, Bomanji, Jamshed, Perren, Aurel, Ell, Peter J, & Reubi, Jean Claude. (2011). Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. Journal of Nuclear Medicine, 52(7), 1073–1078. https://doi.org/10.2967/jnumed.110.085142

Christ E, Wild D, & Reubi JC. (2010). Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review. Endocrinology and Metabolism Clinics of North America, 39(4), 791–800. https://doi.org/10.1016/j.ecl.2010.09.003

Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, Reubi JC, & Bomanji JB. (2010). Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nuclear medicine communications, 31(12), 1025–1032. https://doi.org/10.1097/mnm.0b013e32833f635e

Pattou F, Kerr-Conte J, & Wild D. (2010). GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. New England Journal of Medicine, 363(13), 1289–1290. https://doi.org/10.1056/NEJMc1004547

Schweizer H, Boehm J, Winterer JT, Wild D, Neumann HP, Wiech T, Stubanus M, & Kuehn EW. (2010). Phaeochromocytoma and thrombotic microangiopathy: favourable outcome despite advanced renal failure. (Patent No. 8). 63(8), Article 8. https://doi.org/10.1136/jcp.2010.077511

Wild D, Theodoraki A, Kurzawinski TR, Bomanji J, Reubi JC, Khan R, Bouloux P, & Khoo B. (2010). ‘Running on empty’. European journal of nuclear medicine and molecular imaging, 37(7), 1439–1440. https://doi.org/10.1007/s00259-010-1455-8

Wild, Damian, Wicki, Andreas, Mansi, Rosalba, Behe, Martin, Keil, Boris, Bernhardt, Peter, Christofori, Gerhard, Ell, Peter J., & Maecke, Helmut R. (2010). Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. Journal of Nuclear Medicine, 51(7), 1059–1067. https://doi.org/10.2967/jnumed.110.074914

Christ, Emanuel, Wild, Damian, Forrer, Flavio, Brändle, Michael, Sahli, Rahel, Clerici, Thomas, Gloor, Beat, Martius, Ferdinand, Maecke, Helmut, & Reubi, Jean Claude. (2009). Glucagon-like peptide-1 receptor imaging for localization of insulinomas. Journal of clinical endocrinology and metabolism, 94(11), 4398–4405. https://doi.org/10.1210/jc.2009-1082

Ginj, Mihaela, Zhang, Hanwen, Eisenwiener, Klaus-Peter, Wild, Damian, Schulz, Stefan, Rink, Hans, Cescato, Renzo, Reubi, Jean Claude, & Maecke, Helmut R. (2008). New pansomatostatin ligands and their chelated versions : affinity profile, agonist activity, internalization, and tumor targeting. Clinical Cancer Research, 14(7), 2019–2027. https://doi.org/10.1158/1078-0432.ccr-07-1687

Wild, Damian, Mäcke, Helmut, Christ, Emanuel, Gloor, Beat, & Reubi, Jean Claude. (2008). Glucagon-like peptide 1-receptor scans to localize occult insulinomas. The New England Journal of Medicine, 359(7), 766–768. https://doi.org/10.1056/nejmc0802045

Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, & Maecke HR. (2007). DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. European journal of nuclear medicine and molecular imaging, 34(8), 1198–1208. https://doi.org/10.1007/s00259-006-0347-4